Tcr2 Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Tcr2 Therapeutics Inc (TCRR) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Tcr2 Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Tcr2 Therapeutics Inc | - | - | - | Yes |
| Competitors combined (31) | ||||
| High-Confidence Competitors (2) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
TCRR Stock Performance relative to its Competitors
TCRR Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Century Therapeutics inc | 282.9% | Outperformed |
| 3 | Replimune Group Inc | 282.9% | Outperformed |
| 4 | Exelixis Inc | 282.9% | Outperformed |
| 5 | Agenus Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Tcr2 Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Tcr2 Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Tcr2 Therapeutics Inc |
61.97 | - |
 Amgen Inc |
255,014.76 | 38,903.00 |
 Gilead Sciences Inc |
210,105.45 | 30,988.00 |
 Moderna Inc |
92,077.30 | 2,228.00 |
 Seagen Inc |
43,034.00 | 2,300.35 |
 Exelixis Inc |
17,861.86 | 2,496.86 |
| SUBTOTAL | 629,135.30 | 78,605.01 |
Sign in to see all competitors of Tcr2 Therapeutics Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Tcr2 Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Tcr2 Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Tcr2 Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Phoenix Biotech Acquisition Corp | Company report | 85% |
| Samsara Luggage Inc | Company report | 85% |
| Poseida Therapeutics Inc | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Cabaletta Bio Inc | Company report | 85% |
| Tscan Therapeutics Inc | Company report | 85% |
| Autolus Therapeutics Plc | Company report | 85% |
| Surface Oncology Inc | Company report | 85% |
| Adaptimmune Therapeutics Plc | Company report | 85% |
| Immunocore Holdings Plc | Company report | 85% |
| Century Therapeutics inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Tcr2 Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Tcr2 Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Exelixis Inc | Reportable 100.00 % |
| Immunocore Holdings Plc | Reportable 100.00 % |
| Intellia Therapeutics Inc | Development of Gene Editing Based Therapies 100.00 % |
| Century Therapeutics inc | Single reportable segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Tcr2 Therapeutics Inc .
Tcr2 Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Tcr2 Therapeutics Inc | 62 | - | -2,398,515 |
| Amgen Inc | 255,015 | 2,992,538 | 722,385 |
| Gilead Sciences Inc | 210,105 | 1,822,824 | -227,235 |
| Moderna Inc | 92,077 | 474,043 | -670,426 |
| Seagen Inc | 43,034 | 1,916,959 | -625,187 |
| Exelixis Inc | 17,862 | 2,176,862 | 1,454,397 |
| PEERS TOTAL | 629,073 | 1,882,214 | 54,726 |
Sign in to see all peers for Tcr2 Therapeutics Inc .
Tcr2 Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 76.66 % |
| Exelixis Inc | United States 92.47 % |
| Agenus Inc | US 100.00 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Tcr2 Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.7x | - |
| EV / EBITDA | - | 16.7x | - |
| P/B | 0.3x | 5.1x | -4.8x |
| Return on Equity | -97.81 % | industry aggregate | -110.05 % |
| Return on Invested Capital | -46.67 % | -11.27 % (avg) | -35.40 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Tcr2 Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenue Growth | - | - | - | - |
| Operating Margin | - | - | - | - |
| Return on Invested Capital | -14.53 % | -17.84 % | -15.11 % | -34.82 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Tcr2 Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 110.1 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (58.10 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-21.2% annualized).
Methodology: see Methodology: SWOT Analysis.
Tcr2 Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Tcr2 Therapeutics Inc | 0.78 | 3.84 | - |
| Amgen Inc | 0.49 | 1.31 | 5.27 |
| Gilead Sciences Inc | - | 1.52 | 1.47 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
| Seagen Inc | 0.43 | 3.22 | - |
| Exelixis Inc | 0.84 | 3.37 | - |
Sign in to see all peers for Tcr2 Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Tcr2 Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Tcr2 Therapeutics Inc | Q1 2023 | - | - |
| Amgen Inc | Q3 2026 | +8.5 % | +20.1 % |
| Gilead Sciences Inc | Q3 2026 | +6.8 % | -20.4 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| Seagen Inc | Q3 2023 | +27.1 % | - |
| Exelixis Inc | Q3 2026 | +10.2 % | -51.1 % |
| PEERS TOTAL | +9.9 % | +28.7 % |
Sign in to see all peers for Tcr2 Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Tcr2 Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Tcr2 Therapeutics Inc | Q1 2023 | - | -92.0 % |
| Amgen Inc | Q3 2026 | -9.5 % | +34.6 % |
| Gilead Sciences Inc | Q3 2026 | +0.1 % | +61.2 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
| Seagen Inc | Q3 2023 | +52.8 % | +175.7 % |
| Exelixis Inc | Q3 2026 | +41.2 % | +67.9 % |
Sign in to see all peers for Tcr2 Therapeutics Inc .
Tcr2 Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Tcr2 Therapeutics Inc | - | - | - |
| Amgen Inc | 10.02% | 13.64% | 85.59% |
| Gilead Sciences Inc | - | - | - |
| Moderna Inc | - | - | - |
| Seagen Inc | - | - | - |
| Exelixis Inc | 63.88% | 75.01% | 85.83% |
Sign in to see all peers for Tcr2 Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Tcr2 Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Tcr2 Therapeutics Inc | - | - |
| Amgen Inc | 27.08 | 6.56 |
| Gilead Sciences Inc | - | 6.78 |
| Moderna Inc | - | 41.33 |
| Seagen Inc | - | 18.71 |
| Exelixis Inc | 28.74 | 7.15 |
| PEERS AVERAGE | 296.43 | 8.00 |
Sign in to see all peers for Tcr2 Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.